Soleno Therapeutics Inc Stock News

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Drawing stocks: Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH -1.65%), Soleno Therapeutics, Inc. (NASDAQ:SLNO -1.64%) appeared first on Stocks Equity .

Zacks Investment Research lowered shares of Soleno Therapeutics (NASDAQ:SLNO) from a buy rating to a hold rating in a research report report published on Saturday, Zacks.com reports. According to Zacks, Soleno Therapeutics Inc. is a healthcare company. It develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The Company offers products consists of []

Soleno Therapeutics (NASDAQ:SLNO) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Saturday, Zacks.com reports. According to Zacks, Soleno Therapeutics Inc. is a healthcare company. It develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The Company offers [] The post Soleno Therapeutics (NASDAQ:SLNO) Downgraded to Hold at Zacks Investment Research appeared first on ETF Daily News .

In last trading session, Soleno Therapeutics Inc. (NASDAQ:SLNO) saw 0.63 million shares changing hands with its beta currently measuring 0.38. Companys recent per share price level of $0.57 trading at -$0.05 or -7.87% at ring of the bell on the day assigns it a market valuation of $46.10M. That closing price of SLNOs stock is Buy, Sell Or Hold Soleno Therapeutics Inc. (NASDAQ:SLNO) At $0.57? Read More »

Zacks Investment Research upgraded shares of Soleno Therapeutics (NASDAQ:SLNO) from a hold rating to a buy rating in a report released on Thursday, Zacks.com reports. The brokerage currently has $0.75 price target on the stock. According to Zacks, Soleno Therapeutics Inc. is a healthcare company. It develops and commercializes diagnostics, devices and therapeutics addressing unmet [] The post Soleno Therapeutics (NASDAQ:SLNO) Upgraded by Zacks Investment Research to Buy appeared first on ETF Daily News .

Soleno Therapeutics, Inc. (SLNO) with the stream of -2.90% also noticed, India SeaChange International, Inc. (SEAC) encountered a rapid change of 6.67% in the last hour of Wednesdays trading session. The post Overview of Different Indicators: Soleno Therapeutics, Inc. (NASDAQ:SLNO), SeaChange International, Inc. (NASDAQ:SEAC) appeared first on Stocks Equity .

Soleno Therapeutics, Inc. (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street anal

Equities analysts expect Soleno Therapeutics, Inc. (NASDAQ:SLNO) to post earnings per share (EPS) of ($0.08) for the current quarter, Zacks reports. Zero analysts have made estimates for Soleno Therapeutics earnings. Soleno Therapeutics posted earnings per share of ($0.04) in the same quarter last year, which would indicate a negative year over year growth rate of []

REDWOOD CITY, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treat

European Key Opinion Leaders to Participate in Event European Key Opinion Leaders to Participate in Event

REDWOOD CITY, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treat

Soleno Therapeutics (SLNO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treat

Soleno Therapeutics (SLNO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

REDWOOD CITY, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treat